Test Price
2,800 AED✅ Home Collection Available
MAN1B1 Gene Mental Retardation, Autosomal Recessive Type 15 Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
This molecular genetic test, offered exclusively by DNA Labs UAE under DHA Facility License No. 1143, delivers definitive identification of pathogenic variants in the MAN1B1 gene responsible for autosomal recessive intellectual disability type 15. The test is processed under ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139) and provides a diagnostic sensitivity of 99.9 percent for coding exons and flanking splice sites.
- Accuracy Guarantee: 99.9% analytical sensitivity and specificity achieved through Illumina NGS with deep bioinformatics pipeline and full gene coverage.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Post-test telephonic counseling with a board-certified Consultant Medical Geneticist for comprehensive result interpretation.
- Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The MAN1B1 gene encodes alpha-1,2-mannosidase, an enzyme critical for glycoprotein processing in the endoplasmic reticulum. Loss-of-function variants disrupt N-glycan maturation, leading to a syndromic form of intellectual disability characterized by global developmental delay, truncal obesity, hypotonia, and distinctive facial features. Our assay employs next-generation sequencing to interrogate all coding exons and conserved splice junctions, ensuring detection of missense, nonsense, frameshift, and canonical splice-site alterations. Sanger confirmation is performed for all clinically reported variants to guarantee accuracy.
| Feature | Our NGS Test (MAN1B1) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% Analytical Sensitivity & Specificity for Coding Exons ±10 bp | 99.5% – limited to pre‑targeted known point mutations |
| Methodology | Illumina NGS with Deep Bioinformatics (Full Gene Coverage) | Single‑Gene Sanger Cycle Sequencing |
| Turnaround Time | 3 – 4 Weeks | 4 – 6 Weeks (with reflex steps) |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403):
“Genetic evaluation of MAN1B1-related intellectual disability requires correlation with developmental history, neurological examination, and metabolic screening. A positive result confirms the molecular diagnosis and enables precise recurrence risk counseling for families; a negative result does not exclude other genetic causes of global developmental delay. All patients should maintain current therapies and follow-up with their managing specialist before making any changes to treatment or surveillance plans.”
Advisory: Medication Continuity
⚠ Important Notice Do not discontinue or alter any prescribed medication, therapy, or intervention without direct consultation with your managing clinician. This genetic test is intended to inform diagnosis and family planning, not to replace ongoing medical management.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Individuals unable to provide informed consent or whose legal guardian cannot provide consent on their behalf; patients experiencing an acute medical crisis that compromises safe blood collection (e.g., severe coagulopathy, active sepsis, or hemodynamic instability).
- Emergency Red Flags – Seek Immediate Medical Attention: New-onset uncontrolled seizures, abrupt regression of developmental milestones, acute encephalopathy or confusion, or any sudden neurological deterioration requiring urgent hospital-based evaluation.
Patient FAQ & Clinical Guidance
1. What is the clinical purpose of the MAN1B1 gene test?
This test detects pathogenic variants in the MAN1B1 gene to establish a molecular diagnosis of autosomal recessive intellectual disability type 15. Confirming the genetic cause enables accurate prognosis, guides surveillance for associated features such as truncal obesity and metabolic concerns, and provides families with recurrence risk information for future family planning.
2. How is the sample collected and what is the turnaround time?
A standard peripheral whole blood sample is collected via our VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection service, available seven days a week from 8 AM to 11 PM. Alternatively, samples can be provided at our DHA-licensed laboratory in Dubai Healthcare City. The NGS analysis and bioinformatics interpretation are completed within 3 to 4 weeks from sample receipt.
3. Is this genetic test covered by insurance in the UAE?
DNA Labs UAE provides direct insurance billing verification via WhatsApp at +971 54 548 8731. Many UAE health insurance plans cover medically indicated genetic testing for intellectual disability when prior approval is obtained. We recommend contacting your insurer or our billing team to confirm coverage details before sample collection.
UAE Regulatory & Data Privacy Adherence
This genetic testing service operates in full compliance with the UAE’s data protection and health information governance frameworks. All patient data, including genetic test results and counseling records, are handled under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety, patient consent, and medical liability are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is licensed by the Dubai Health Authority under Facility License No. 1143 and operates from Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | MAN1B1 Gene Mental Retardation, Autosomal Recessive Type 15 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks (21 – 28 calendar days from sample receipt) |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) or saliva (Oragene collection kit) |
| Methodology Used | Illumina Next-Generation Sequencing (NGS) with deep bioinformatics analysis and Sanger confirmation of all reported variants |
| ICD-10-CM Code | F78 (Other intellectual disabilities) |
| LOINC Code | 21636-6 (Gene mutations identified in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians